EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Risk-Stratified Screening for Colorectal Cancer Using Genetic and Environmental Risk Factors: A Cost-Effectiveness Analysis Based on Real-World Data

Rosita van den Puttelaar, Reinier G S Meester, Elisabeth F P Peterse, Ann G Zauber, Jiayin Zheng, Richard B Hayes, Yu-Ru Su, Jeffrey K Lee, Minta Thomas, Lori C Sakoda, Yi Li, Douglas A Corley und 3 weitere

Clinical Gastroenterology and Hepatology · 2023-12 · 21 (13) · 3415-3423.e29

DOI: 10.1016/j.cgh.2023.03.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-12. Verfasst von Rosita van den Puttelaar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: r.vandenputtelaar@erasmusmc.nl. Hauptthemen laut MEDLINE: Cost-Effectiveness Analysis, Colorectal Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Previous studies on the cost-effectiveness of personalized colorectal cancer (CRC) screening were based on hypothetical performance of CRC risk prediction and did not consider the association with competing causes of death. In this study, we estimated the cost-effectiveness of risk-stratified screening using real-world data for CRC risk and competing causes of death. METHODS: Risk predictions for CRC and competing causes of death from a large community-based cohort were used to stratify individuals into risk groups. A microsimulation model was used to optimize colonoscopy screening for each risk group by varying the start age (40-60 years), end age (70-85 years), and screening interval (5-15 years). The outcomes included personalized screening ages and intervals and cost-effectiveness compared with uniform colonoscopy screening (ages 45-75, every 10 years). Key assumptions were varied in sensitivity analyses. RESULTS: Risk-stratified screening resulted in substantially different screening recommendations, ranging from a one-time colonoscopy at age 60 for low-risk individuals to a colonoscopy every 5 years from ages 40 to 85 for high-risk individuals. Nevertheless, on a population level, risk-stratified screening would increase net quality-adjusted life years gained (QALYG) by only 0.7% at equal costs to uniform screening or reduce average costs by 1.2% for equal QALYG. The benefit of risk-stratified screening improved when it was assumed to increase participation or costs less per genetic test. CONCLUSIONS: Personalized screening for CRC, accounting for competing causes of death risk, could result in highly tailored individual screening programs. However, average improvements across the population in QALYG and cost-effectiveness compared with uniform screening are small.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Effectiveness AnalysisColorectal NeoplasmsHumansMiddle AgedAdultAgedAged, 80 and overCost-Benefit AnalysisEarly Detection of CancerColonoscopyMass Screening

Stichwörter der Autor:innen

Colorectal CancerCost-EffectivenessEnvironmental RiskGenetic RiskScreening

Autor:innen und Institutionen

  • Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: r.vandenputtelaar@erasmusmc.nl.
  • Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Division of Epidemiology, Department of Population Health, New York University School of Medicine, New York, New York.

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

van den Puttelaar, R., Meester, R. G. S., Peterse, E. F. P., Zauber, A. G., Zheng, J., Hayes, R. B., Su, Y. R., Lee, J. K., Thomas, M., Sakoda, L. C., Li, Y., Corley, D. A., Peters, U., Hsu, L., & Lansdorp-Vogelaar, I. (2023). Risk-Stratified Screening for Colorectal Cancer Using Genetic and Environmental Risk Factors: A Cost-Effectiveness Analysis Based on Real-World Data. Clinical Gastroenterology and Hepatology, 21(13), 3415-3423.e29. https://doi.org/10.1016/j.cgh.2023.03.003

Vancouver

van den Puttelaar R, Meester RGS, Peterse EFP, Zauber AG, Zheng J, Hayes RB, et al. Risk-Stratified Screening for Colorectal Cancer Using Genetic and Environmental Risk Factors: A Cost-Effectiveness Analysis Based on Real-World Data. Clinical Gastroenterology and Hepatology. 2023;21(13):3415-3423.e29. doi:10.1016/j.cgh.2023.03.003

BibTeX
@article{vandenPuttelaar2023,
  author = {van den Puttelaar, Rosita and Meester, Reinier G S and Peterse, Elisabeth F P and Zauber, Ann G and Zheng, Jiayin and Hayes, Richard B and Su, Yu-Ru and Lee, Jeffrey K and Thomas, Minta and Sakoda, Lori C and Li, Yi and Corley, Douglas A and Peters, Ulrike and Hsu, Li and Lansdorp-Vogelaar, Iris},
  title = {Risk-Stratified Screening for Colorectal Cancer Using Genetic and Environmental Risk Factors: A Cost-Effectiveness Analysis Based on Real-World Data},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2023},
  volume = {21},
  number = {13},
  pages = {3415--3423.e29},
  doi = {10.1016/j.cgh.2023.03.003}
}
Kostenlos starten →